STOCK TITAN

SeaStar Medical Holding Corp - ICU STOCK NEWS

Welcome to our dedicated news page for SeaStar Medical Holding (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SeaStar Medical Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SeaStar Medical Holding's position in the market.

Rhea-AI Summary
SeaStar Medical Holding Corporation (ICU) announces publication of a manuscript discussing the role of chronic systemic inflammation in heart failure patients and the potential application of the Adult Selective Cytopheretic Device to improve outcomes. The manuscript reviews the positive effect of the device in a first-in-human case report, leading to a Breakthrough Device Designation from the FDA. SeaStar also received FDA approval for the Pediatric SCD for use in children with acute kidney injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.88%
Tags
none
-
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) receives FDA approval for SCD-PED, the first product in the Quelimmune product family, for pediatric use in acute kidney injury cases due to sepsis or septic conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.45%
Tags
none
-
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) has announced the issuance of Canadian Patent No. 2814586, expanding its international patent rights for the Selective Cytopheretic Device (SCD) technology. The new patent covers SCD cartridges for treating activated leukocytes and platelets, as well as their use in processing activated leukocytes and platelets. This development presents a significant opportunity to improve the treatment of dysregulated hyperinflammatory responses and potentially reverse organ injury. CEO Eric Schlorff highlighted the innovative and proven approach of SCD in targeting highly active inflammatory cells to quell hyperinflammatory responses resulting from various conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) has announced a securities purchase agreement with an institutional investor to purchase over 10 million shares of common stock in a registered direct offering, along with the issuance of Series A and Series B warrants. The offering is expected to generate approximately $9.0 million in gross proceeds for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.54%
Tags
offering
-
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) appoints healthcare industry veteran David A. Green as Chief Financial Officer, effective January 10, 2024, as the company prepares for its first commercial launch for the Selected Cytopheretic Device Pediatric (SCD-PED).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
management
-
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) has announced the issuance of U.S. Patent No. 11,866,730 for its Selective Cytopheretic Device (SCD) to treat subjects with inflammatory conditions. The SCD is a first-in-class, cell-directed extracorporeal therapy that selectively targets highly active inflammatory cells to quell the inflammatory response. This patent significantly fortifies the company's intellectual property portfolio and supports its strategy to validate the technology’s application across multiple high-value clinical indications. CEO Eric Schlorff highlighted the importance of controlling uncontrolled hyperinflammation, which can lead to vital organ damage and even death. The SCD therapy works to selectively target the most highly activated cells responsible for inflammation to potentially reverse the damage they cause. The newly issued patent covers methods for using SCD cartridges to treat inflammatory conditions by extracorporeally sequestering activated leukocytes and/or platelets and inhibiting or deactivating their inflammatory action, as well as methods for processing activated leukocytes and/or platelets. The patent’s claimed methods require the SCD cartridge to have specific ratios of surface area for sequestering activated leukocytes and/or platelets to SCD inner volume. Unlike pathogen removal and other blood-purification tools, the SCD selectively targets the most highly activated proinflammatory neutrophils and monocytes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) announces enrollment of 12 subjects in the NEUTRALIZE-AKI pivotal clinical trial for its patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy. The company expects to receive FDA approval for its SCD Pediatric (SCD-PED) within the next 30 to 45 days and to commence commercialization in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.91%
Tags
none
-
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) announces the formation of the SeaStar Medical Scientific Advisory Board (SAB), comprised of world-renowned international pediatric and adult clinical experts to advise on technology capabilities, share insights on emerging healthcare trends, and advise on critical care and acute kidney injury (AKI) clinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
management
-
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) Reports Financial Results and Business Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
earnings
Rhea-AI Summary
SeaStar Medical Holding Corporation announces FDA's Approvable Letter for their Selective Cytopheretic Device Pediatric (SCD-PED) for use in children with acute kidney injury and sepsis. The letter indicates that SeaStar's HDE application meets the requirements for an Approval Order, with minor modifications and revisions needed before commercialization. SeaStar expects to commence commercialization by the end of 2023 or Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
SeaStar Medical Holding Corp

Nasdaq:ICU

ICU Rankings

ICU Stock Data

51.47M
35.55M
17.4%
1.41%
3.83%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Denver